Google
Cara A. Rosenbaum, MD
Assistant Professor of MedicineDivision of Hematology
and Medical Oncology
Weill Cornell Medicine
Staff Oncologist
New York-Presbyterian Hospital
New York, New York, United States
Dr. Cara Rosenbaum is Assistant Professor of Medicine at Weill Cornell Medical College and staff oncologist at New York-Presbyterian Hospital in New York City. She is actively involved in clinical and translational research in AL amyloidosis, and serves as principle or co-investigator on numerous clinical and translational research trials that incorporate novel therapies for her patients. She is certified by the American Board of Internal Medicine in Hematology.
Dr. Rosenbaum received her undergraduate degree from Columbia University and medical degree with honors from the University of Illinois College of Medicine. She completed her Internal Medicine residency and combined fellowship in Hematology and Medical Oncology at the University of Chicago, subsequently joining the faculty and developing a clinical and research amyloidosis program serving the greater Midwest. While at University of Chicago, she worked closely with the National Cancer Institute and researchers at the national level to develop cancer clinical trials for new therapies in multiple myeloma, lymphoma and leukemia while serving as Executive Officer of the oncology clinical research organization, Alliance for Clinical Trials in Oncology. She was recruited to Weill Cornell Medical College and New York-Presbyterian Hospital in 2017 and specializes in the treatment of amyloidosis, including advanced cardiac amyloidosis. She conducts research and develops new therapies for amyloidosis and multiple myeloma, working closely with radiation oncologists, surgeons, cardiologists, nephrologists and other specialists to support an integrated approach to patient care along with performing stem cell transplants.
Dr. Rosenbaum has published numerous peer-reviewed articles, reviews, editorials and book chapters. She is a member of several scientific organizations including the American Society of Hematology, International Myeloma Society and the International Society of Amyloidosis and is actively involved with national amyloidosis support groups.
